MAZE THERAPEUTICS INC
CUSIP: 578784100
MAZE THERAPEUTICS INC (MAZE) — institutional ownership and SEC 13F holdings data. Source: SEC EDGAR 13F filings.
About
Maze Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on translating genetic insights into novel therapies for patients with serious diseases. The company utilizes its proprietary Compass Platform to identify genetic variants and map disease biology to develop small molecule precision medicines. Maze is primarily advancing programs aimed at treating kidney diseases, including certain forms of focal segmental glomerulosclerosis (FSGS) and polycystic kidney disease. By leveraging human genetics, the company aims to create targeted treatments that address the underlying mechanisms of these conditions.
Institutional Holders
Source: SEC EDGAR 13F-HR filings from institutional investment managers.
Try asking...